Targeted Nanocarriers for Systemic Delivery of IRAK4 Inhibitors to Inflamed Tissues

The delivered IRAK4 inhibitor markedly abated inflammation and dramatically suppresses paw edema, mitigated colitis symptoms, and reduced proinflammatory cytokine levels in the affected tissues.